| Biomarker ID | 532 |
| PMID | 20473923 |
| Year | 2010 |
| Biomarker | KLK15 (kallikrein-related peptidase) |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | High levels associated with shorter progression-free survival. |
| Odds Ratio/Hazard Ratio/Relative Risk | Univariate: HR: 2.229 (95% CI: 1.353–3.673); Multivariate: HR: 1.802 (95% CI:1.037–3.132); Step Wise Selection: HR: 1.819 (95% CI: 1.053-3.141) |
| Effect on Pathways | Pathways Include:-Intrinsic Prothrombin Activation Pathway,MSP-RON Signaling, PPAR Alpha Pathway,Blood Coagulation Cascade |
| Experiment | PSA recurrence Vs No PSA recurrence |
| Type of Biomarker | Prognostic |
| Cohort | For immunohistochemical expression of KLK15, 193 patients were included out of which 63 had PSA defined recurrence and 130 did not have PSA defined recurrence, with Avg time= 27 months. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | Univariate: p = 0.002; Multivariate: p=0.037; StepWise Inclusion: p=0.032 |
| Method Used | Immunohistochemistry |
| Clinical | No |
| Remarks | Forward and backward stepwise elimination procedures including all six variables (Age, PSA, Tumor Stage, Tumor Grade, Surgical Margin, KLK15) |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on Independent Patient Dataset |
| Technical Name | KLK15 |